Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 14/20 | 0.70 |
| ▸ | CHRNA4 | P43681 | 14/20 | 0.70 |
| ▸ | CHRNB4 | P30926 | 9/20 | 0.70 |
| ▸ | CHRNA3 | P32297 | 9/20 | 0.70 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.70 |
| ▸ | CHRNG | P07510 | 3/20 | 0.70 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.70 |
| ▸ | CHRND | Q07001 | 3/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412259 | 0.82 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Hydrochloric Acid SCHEMBL4408107 | 0.81 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL2062192 | 0.72 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL4406668 | 0.72 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL4405016 | 0.72 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL4406586 | 0.72 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL4406458 | 0.72 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL29761232 | 0.72 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL5767352 | 0.71 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Hydrochloric Acid SCHEMBL5535154 | 0.70 | CHRNB2 (0.96) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082555-A1 | Use of gaba, inverse agonists in combination with nicotine receptor partial agonist, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders | PFIZER INC | 2004-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082555-A1 | Use of gaba, inverse agonists in combination with nicotine receptor partial agonist, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders | CHRNE, CHRNA10, GABRE | CHRNB2 16/4885CHRNA4 10/4885CHRNB4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.